BioVie Inc. (BIVI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for BioVie Inc. in 2026. The next earnings report is expected on September 2, 2026.
Next earnings date
02 Sep 2026
In 13 days
EPS estimate
-0.52
Revenue estimate
0
Past earnings
No dividend history available.
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.
BioVie Inc. (BIVI) is scheduled to report earnings on September 2, 2026.
BioVie Inc. (BIVI) last reported earnings on August 13, 2026.
BioVie Inc. (BIVI) is listed on Nasdaq.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.